Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Arvinas
Biotech
Xaira, Anthos, CureVac & more—Chutes & Ladders
Ousted former Stanford president to lead new billion-dollar biotech. Fresh off BMS buy, Karuna’s ex-CEO to helm Anthos. CureVac names new CBO.
Max Bayer
,
Gabrielle Masson
,
Andrea Park
Apr 26, 2024 8:30am
Novartis pays $150M for Arvinas' prostate tumor protein degrader
Apr 11, 2024 8:04am
Bayer undergoes leadership shake-up—Chutes & Ladders
Mar 22, 2024 9:30am
Arvinas advances anti-resistance cancer drug on sign of efficacy
Jun 8, 2023 9:30am
Amarin CEO abruptly resigns—Chutes & Ladders
Apr 7, 2023 9:30am
Pfizer's $1B protein degradation bet yields 3% response rate
Nov 22, 2022 9:40am